Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon alfa-2a, ATC L03AB11 für die Zeit 01.08.2026 - 31.07.2028

DAK-GesundheitHamburg, GermanyEUR 1 / ~EUR 1717 days leftopen

Registrieren zum Speichern Documents (1)

Opportunity Score

Confidence: 60%

Complexity: low

717 days

Deadline

supplies

Contract

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

Non-exclusive discount agreement (Open-House) for Peginterferon alfa-2a (ATC L03AB11) with DAK-Gesundheit, valid from 01.08.2026 to 31.07.2028. Open to all pharmaceutical companies; no competitive award. Submission via email only, in German. Contract automatically ends if an exclusive contract is awarded.

Strengths

Documents available

Open procedure

Low complexity

Key Requirements

Submission via email only to [email protected].
Documents must be in German.
Required documents: Angebotsschreiben (offer letter), signed contract (acceptance of terms), filled Annexes 1 and 2.

Buyer

Name

DAK-Gesundheit

Location

Hamburg, DEU

[email protected]

Website

www.dak.de

Identifier

DE48698890

Lots (1)

#LOT-0001Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon alfa-2a, ATC L03AB11 für die Zeit 01.08.2026 - 31.07.2028

Open-House procedure for a non-exclusive discount agreement on pharmaceuticals containing Peginterferon alfa-2a. Any interested pharmaceutical company can join during the contract period by submitting required documents via email. The contract ends automatically if an exclusive contract is concluded.

EUR 133600000DEU